Salvatore et al. described a 17.4% positivity rate of HER2 overexpression in BTC and 27.9% in ampulla Vater carcinoma, in line with the median range of HER2+ in PDAC. Here, ERBB2 is linked to carcinoma of the ampulla of vater.